Patents by Inventor Austin L. Gurney

Austin L. Gurney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20130280277
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 24, 2013
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
  • COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
    Publication number: 20130266569
    Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 10, 2013
    Inventors: Austin L. GURNEY, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal
  • Methods for identifying and isolating cells expressing a polypeptide
    Patent number: 8551715
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: October 8, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond
  • Frizzled-binding agents and their use in screening for WNT inhibitors
    Patent number: 8551789
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: October 8, 2013
    Assignee: OncoMed Pharmaceuticals
    Inventor: Austin L. Gurney
  • NOTCH BINDING AGENTS AND ANTAGONISTS AND METHODS OF USE THEREOF
    Publication number: 20130260455
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: March 1, 2013
    Publication date: October 3, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20130252326
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 26, 2013
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventors: AUSTIN L. GURNEY, AARON KEN SATO, FUMIKO TAKADA AXELROD, TIMOTHY CHARLES HOEY, SANJEEV H. SATYAL, SATYAJIT SUJIT KUMAR MITRA
  • Method for Making Heteromultimeric Molecules
    Publication number: 20130253172
    Abstract: The present invention provides methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising said molecules. The method includes introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 26, 2013
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventors: AUSTIN L. GURNEY, AARON K. SATO
  • Antibodies to lymphotoxin-?
    Patent number: 8541552
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: September 24, 2013
    Assignee: Genetech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • NOTCH1 BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20130243774
    Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 19, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Edward Thein Htun van der HORST, Austin L. GURNEY, Timothy Charles HOEY, Maureen Fitch BRUHNS, Fumiko Takada AXELROD
  • Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
    Patent number: 8507442
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: August 13, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • NOTCH1 receptor antibodies and methods of treatment
    Patent number: 8435513
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: May 7, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
  • Methods of treatment by administering antibodies to notch receptors
    Patent number: 8425903
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: April 23, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • RSPO Binding Agents and Uses Thereof
    Publication number: 20130095116
    Abstract: The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: July 13, 2012
    Publication date: April 18, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
  • BONE MORPHOGENETIC PROTEIN RECEPTOR BINDING AGENTS AND METHODS OF THEIR USE
    Publication number: 20130089560
    Abstract: The present invention provides bone morphogenetic protein receptor (BMPR) binding agents, such as antibodies, and compositions comprising said binding agents. The binding agents are useful to treat diseases such as cancer.
    Type: Application
    Filed: March 17, 2011
    Publication date: April 11, 2013
    Applicant: OncoMed Pharmaceuticals Inc
    Inventors: Cecile Chartier-Courtaud, Austin L. Gurney
  • WNT-Binding Agents and Uses Thereof
    Publication number: 20130045209
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human Wnt(s) are provided. A conserved domain within Wnt that is suitable as a target for anti-cancer agents is also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: January 12, 2011
    Publication date: February 21, 2013
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventor: Austin L. Gurney
  • ANTIBODIES TO LYMPHOTOXIN-ALPHA
    Publication number: 20130011412
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Application
    Filed: July 6, 2012
    Publication date: January 10, 2013
    Applicant: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • Antibodies that bind to PRO286
    Patent number: 8349329
    Abstract: The invention relates to the identification and isolation of novel DNAs encoding the human Toll proteins PRO285, PRO286, and PRO358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PRO285, or PRO286, or PRO358 Toll protein.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: January 8, 2013
    Assignee: Genetech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
  • WISP polypeptides and nucleic acids encoding same
    Patent number: 8350008
    Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: January 8, 2013
    Assignee: Genentech, Inc.
    Inventors: David Botstein, Robert L. Cohen, Audrey D. Goddard, Austin L. Gurney, Kenneth J. Hillan, David A. Lawrence, Arnold J. Levine, Diane Pennica, Margaret Ann Roy, William I. Wood
  • Jagged-Binding Agents and Uses Thereof
    Publication number: 20120301489
    Abstract: Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer.
    Type: Application
    Filed: November 19, 2010
    Publication date: November 29, 2012
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
  • Notch-Binding Agents and Antagonists and Methods of Use Thereof
    Publication number: 20120288496
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Application
    Filed: May 15, 2012
    Publication date: November 15, 2012
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki